Today we reported our third quarter 2024 financial results and recent business highlights.?To learn more about our progress and upcoming milestones, read the full press release here: https://lnkd.in/ej4bZxKR
Sensei Bio
生物技术
Rockville，Maryland 3,316 位关注者
We follow the immune system’s teachings to discover new treatments that inspire the body to fight cancer.
关于我们
Sensei Biotherapeutics is an immuno-oncology company that is dedicated to understanding and selectively interacting with the tumor microenvironment in order to tilt the immune system against cancer. We are leveraging our TMAb? platform to develop highly selective therapeutics that have the potential to alter the relationship between host immune cells and cancer so that the tumor is recognized and treated as if it were an infection. Our team is comprised of lifelong learners striving for insight at the intersection of immunology, oncology and biology. We are driven to apply our scientific curiosity to the critical needs faced daily by people who are diagnosed with cancer and the physicians who treat them. We stay humble, always follow the data, and believe that our deep knowledge of cancer biology, the tumor microenvironment, and immunology will lead us to effective therapies.
- 网站
-
https://www.senseibio.com
Sensei Bio的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 总部
- Rockville，Maryland
- 类型
- 上市公司
- 创立
- 1999
- 领域
- Immuno-oncology、Cancer vaccines、Antibodies、Companion diagnostics和Chimeric Antigen Receptor - T Cells
地点
Sensei Bio员工
动态
-
We look forward to presenting at PEGS Europe: Protein and Antibody Engineering Summit and Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. For additional details read the full press release here:?https://lnkd.in/eNDR5DFg #PEGSEurope #SITC2024
-
-
This week, our Senior Director, Biologics Discovery & Early Development, Thomas Thisted PhD, presented an overview of our first conditionally active bispecific program, SNS-201, at the 15th Annual World Bispecific Summit. View the presentation here: https://lnkd.in/eb-383u6
-
-
We’re excited to present preclinical data on our conditionally active SNS-103 program targeting CD39 at the upcoming CRI-ENCI Eighth International Cancer Immunotherapy Conference. More info here:?https://lnkd.in/e4vrVgME
-
-
This month, Sensei’s management will present at the H.C. Wainwright & Co., LLC 26th Annual Global Investment Conference and the Cantor Fitzgerald Global Healthcare Conference. For additional details read the full press release: https://lnkd.in/dRECbpNK
-
-
Earlier this month, our Boston and Rockville colleagues converged in the Poconos for our third annual science retreat, where we shared key learnings featuring scientific presentations from our team and celebrated our recent progress. We were also joined by keynote speaker, Dr. Andrea Cercek, gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center, who sparked insightful discussions about the treatment landscape and high unmet needs of patients. During the retreat, our intellectual pursuits were balanced with some much-needed time in nature, enjoying team-building exercises, and moments of relaxation in the stunning Poconos landscape. A big thank you to everyone who made this a memorable and productive experience. Your enthusiasm, collaboration, and dedication are what drive our success. See you back at the office!
-
Today we reported our second quarter 2024 financial results and provided a corporate update. ?To learn more about our recent advancements and upcoming milestones, read the full press release here:?https://lnkd.in/eHGh9e3Y
-
-
Our SNS-101 poster is up. Please come by and say hi. We’re in Hall A, poster 79. #ASCO24
-
-
Don’t miss our investor webcast on Monday, June 3 at 8:00 am ET, featuring Shiraj Sen, Medical Oncologist and Director of Clinical Research at NEXT Oncology, Dallas, and a principal investigator for the SNS-101 study. The live event can be assessed here: https://lnkd.in/eGRRC9hu? ? We will discuss the clinical data from the Phase 1 dose escalation study of SNS-101, being presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, June 1, 2024.?#ASCO2024 ? SNS-101 is a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation). Tune in!?? ? For additional detail, read the full press release here: https://lnkd.in/epX3Y2bY
-
-
Next week, Company’s management will present a corporate update at Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 6, 2024 at 8:30 a.m. ET.?? ? To register and tune in for this event, click here: https://lnkd.in/dSYYmrgB ? For additional details read the full press release: https://lnkd.in/dKWyy5-y ? #JefferiesHealthcare?
-